<DOC>
	<DOC>NCT01040585</DOC>
	<brief_summary>The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).</brief_summary>
	<brief_title>Cost Effectiveness Of Linezolid In Central America</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study. Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions. Adult men or women with nosocomial pneumonia not associated to a ventilator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>cost effectiveness</keyword>
	<keyword>linezolid</keyword>
	<keyword>ventilator acquired pneumonia</keyword>
	<keyword>central america</keyword>
</DOC>